Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

Michael Y. Shapira, Igor B. Resnick, Sunwen Chou, Avidan U. Neumann, Nell S. Lurain, Thomas Stamminger, Orit Caplan, Niveen Saleh, Thomas Efferth, Manfred Marschall, Dana G. Wolf

Research output: Contribution to journalArticle

111 Scopus citations

Abstract

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

Original languageEnglish (US)
Pages (from-to)1455-1457
Number of pages3
JournalClinical Infectious Diseases
Volume46
Issue number9
DOIs
StatePublished - May 1 2008

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Shapira, M. Y., Resnick, I. B., Chou, S., Neumann, A. U., Lurain, N. S., Stamminger, T., Caplan, O., Saleh, N., Efferth, T., Marschall, M., & Wolf, D. G. (2008). Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clinical Infectious Diseases, 46(9), 1455-1457. https://doi.org/10.1086/587106